Join       Register       Log In       Contact
page shadow



From 7 February, children aged two to five will have immediate and free access to Kalydeco® (ivacaftor)—a life-changing drug that addresses the causes of cystic fibrosis rather than just the symptoms.

Previously, only children six years of age and older with the G551D or other class III gating mutations had subsidised access to Kalydeco.

Read More

[Source: Assistant Minister for Health]

Actions: E-mail | Permalink |